European Centre for Disease Prevention and Control

Findings Spotlight Urgent Need for Europe to Step-up on AIDS, says AHF

Retrieved on: 
Wednesday, September 20, 2023
AIDS, Philanthropy, Public Policy, Government, Health, Healthcare Reform, Advocacy Group Opinion, Foundation, AHF, HIV/AIDS, Diagnosis, Policy, Investment, HIV, AIDS Healthcare Foundation, European Centre for Disease Prevention and Control, ECDC, Medical device

“Progress in curbing new HIV transmissions in Europe and globally is far too slow to meet the global target of ending AIDS by 2030.

Key Points: 
  • “Progress in curbing new HIV transmissions in Europe and globally is far too slow to meet the global target of ending AIDS by 2030.
  • To win the battle against AIDS, all people living with HIV must know their status, stay on treatment, and remain virally suppressed,” said AHF Chief of Global Advocacy and Policy Terri Ford.
  • “But those critical aspects of the AIDS response aren’t possible without increased investments by countries to find people who don’t know they’re HIV positive and get and retain them in care.
  • From January to August 2023, AHF teams in Europe tested over 125,000 people for HIV.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Retrieved on: 
Saturday, June 10, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Antibiotics, Vaccine, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • Recent discovery of plasmid-mediated transferable colistin resistance genes have shown the ease with which resistance can spread in bacterial populations.
  • No cross-resistance with standard of care antibiotics was observed and the demonstrated Enterobacteriaceae-specificity versus broad-spectrum activity supports continued development for this class of antibiotics for the potential management and treatment of antimicrobial resistant pathogens.

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carba

Retrieved on: 
Wednesday, June 7, 2023
Enterobacteriaceae, University of Zurich, XDR, Probability, The BMJ, University, Medical journal, Prevalence, Science Advances, Infection, Colistin, AMR, European Centre for Disease Prevention and Control, USD, Klebsiella pneumoniae, CDC, Death, MDR, MICS, Patient, Manuscript, ECDC, Korea Disease Control and Prevention Agency, Klebsiella, Mortality, WHO, Lancet, Gene, Escherichia coli, World Health Organization, Pharmaceutical industry, Vaccine, Antibiotics, Science, Spexy Beast, Tata LPTA

The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .

Key Points: 
  • The manuscript, titled “Peptidomimetic Antibiotics Disrupt the Lipopolysaccharide Transport Bridge of Drug-Resistant Enterobacteriaceae,” is available online in the international peer-reviewed journal Science Advances at: https://www.science.org/doi/10.1126/sciadv.adg3683 .
  • Antimicrobial resistance (AMR) has emerged as a significant threat for both patients and healthcare systems.
  • In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths and an estimated USD 4.6 billion in healthcare costs.
  • The compounds showed potent in vivo efficacy, especially in lung infection models as well as a promising in vitro and in vivo safety profile.

Tick-borne encephalitis virus in the UK – what it is and how to protect yourself

Retrieved on: 
Monday, April 17, 2023
Vaccine, Infection, UK Health Security Agency, Tropical and subtropical dry broadleaf forests, Vaccination, Tick-borne encephalitis, Central nervous system, Lyme disease, Nerve, Czech Republic, Fever, DEET, Tick, Encephalitis, Health, Skin, Clothing, Weakness, Brain, Epistasis, Inflammation, New Forest, European Centre for Disease Prevention and Control, Incidence, Hospital, Climate change, Walking, Notifiable disease, Patient, TBE, Security agency, Risk, Blood, Control, Confusion, Infant, NHS, Headache, Death, Virus, Meningitis, Fatigue, Disease, Pharmaceutical industry, Pig

TBE is a disease that can lead to inflammation in the brain and is caused by a virus transmitted by the bite of a tick.

Key Points: 
  • TBE is a disease that can lead to inflammation in the brain and is caused by a virus transmitted by the bite of a tick.
  • The incidence in Europe was 0.9 cases per 100,000 people in 2020, but this shows significant variation by country.
  • This virus wasn’t present in the UK until recent years.
  • Taken together, this evidence suggests that the TBE virus is now successfully circulating in the UK, albeit at low levels.

How did it get here?

    • The virus can be transferred from infected to non-infected ticks when both feed on the same host.
    • Ticks infected with TBE virus have also been detected in the New Forest and the North Yorkshire Moors.
    • Slight differences have been found in the genetic background between these viruses, suggesting there have been introductions from multiple locations.

Symptoms

    • The effects of this virus can range from having no symptoms at all, to fever, fatigue and body pains, through to infection of the central nervous system where it results in inflammation (meningitis to severe encephalitis) that can lead to long-term neurological damage or death.
    • More serious symptoms to look out for that may indicate encephalitis include severe headache, a stiff neck, confusion, and weakness in the arms and legs.

Preventing TBE

    • There is a vaccine that has been used to prevent TBE in endemic regions for many years.
    • While the levels of TBE virus are low in the UK, vaccination is probably not justifiable, but this needs to be actively monitored.
    • The vaccine is also worth considering for people visiting a country where TBE is common and planning to do outdoor activities while there.
    • Also, enhanced surveillance of ticks will be important to help us understand TBE risk in different areas of the UK.

Press release - Parliament’s Public Health Subcommittee begins work

Retrieved on: 
Thursday, March 23, 2023
ENVI, Food safety, European Centre for Disease Prevention and Control, ECR, S&D, Public, EPP, Committee, PL, European Medicines Agency, Member of the European Parliament, Metz, Vice Chair of the Federal Reserve, Parliament, RO, Public health, Patient, European, Bioterrorism, Control, Environment, Bartosz, Medical device, EU

The new subcommittee on public health (SANT) elected MEP Bartosz Arłukowicz as Chair, as well as the four Vice-Chairs, at its constitutive meeting today.

Key Points: 
  • The new subcommittee on public health (SANT) elected MEP Bartosz Arłukowicz as Chair, as well as the four Vice-Chairs, at its constitutive meeting today.
  • Following his election, SANT Chair Bartosz Arłukowicz said: “Setting up the Public Health Subcommittee follows on naturally from the work carried out by the Special Committee on Beating Cancer (BECA).
  • Background
    In February 2023, Parliament approved the creation of the public health subcommittee, made up of 30 full members.
  • The Committee on the Environment, Public Health and Food Safety (ENVI) remains responsible for examining and voting on legislative proposals.

Press release - MEPs nominated to new public health subcommittee

Retrieved on: 
Wednesday, March 15, 2023
Member of the European Parliament, Control, Public health, Committee, Food safety, EP, Environment, Name, European Centre for Disease Prevention and Control, European Medicines Agency, Public, Bioterrorism, ENVI, Medical device

The names of members who will be sitting on the new Subcommittee on Public Health (SANT) were announced in plenary on Wednesday morning.

Key Points: 
  • The names of members who will be sitting on the new Subcommittee on Public Health (SANT) were announced in plenary on Wednesday morning.
  • MEPs voted during the February 2023 plenary session to set up a subcommittee on public health, under the umbrella of the Committee on the Environment, Public Health and Food Safety (ENVI).
  • The procedure to nominate MEPs to a committee is set out in Rule 209 of the EP rules of procedure.
  • Background
    According to its approved mandate, the public health subcommittee will deal with programmes and specific actions in the field of public health, pharmaceutical and cosmetic products, health aspects of bioterrorism, the European Medicines Agency, and the European Centre for Disease Prevention and Control.

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Retrieved on: 
Wednesday, January 4, 2023
Death, World Health Organization, CE, European Centre for Disease Prevention and Control, Environment, HPV, Growth, COVID-19, Diagnosis, Control, Risk, Nature, Cervical cancer, Union, Hepatitis B, Multimedia, Monkeypox, Therapy, Herpes simplex, Infection, Degenerative disease, Woman, Vaccine, Malaria, EU

LONDON, Jan. 4, 2023 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives.

Key Points: 
  • The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent.
  • These tests will cover more genotypes, have shorter processing times and lower costs than the currently available HPV tests in Europe.
  • Founded in 2013, Virax Biolabs is an Innovative Biotechnology company focused on the diagnosis of and the detection of immune responses to viral diseases.
  • T-Cell testing can be particularly effective in the management and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.

Fatigue Puts U.S. Businesses at Risk of New COVID Wave, Advises SaferMe

Retrieved on: 
Tuesday, October 18, 2022
Fatigue, Infection, Hand, COVID, Organization, Control, Pandemic fatigue, European Centre for Disease Prevention and Control, COVID-19 deaths, Technology, CEO, Face, Safety, GLOBE, Death, EU, COVID-19, Animal, Risk management

"What is concerning is that many U.S companies are developing COVID fatigue and are becoming complacent with their planning, despite growing health indicators in Europe.

Key Points: 
  • "What is concerning is that many U.S companies are developing COVID fatigue and are becoming complacent with their planning, despite growing health indicators in Europe.
  • It is just good business continuity protocol to ensure that pandemic plans are always up to date," says Clint Van Marrewijk, CEO and founder of SaferMe.
  • Businesses have a duty of care to look after their employees and all visitors on company premises," adds Van Marrewijk.
  • SaferMe is one of the world's leading pandemic readiness and workforce safety companies, and it advises governments, Fortune 500 businesses, and some of the world's most prominent brands in over 30 countries.

European Clinical Laboratory Services Market 2022: Increased Support for Europe's Beating Cancer Plan for Improved Early Detection, Treatment and Care - ResearchAndMarkets.com

Retrieved on: 
Friday, April 1, 2022
Health, Oncology, Clinical Trials, Population, Diagnosis, World Health Organization, WHO, Labs, Health, POCT, IVD, Research, European Centre for Disease Prevention and Control, Medicine, ECDC, Laboratory, Infection, COVID-19, Solution, Patient, Fine chemical, Pharmaceutical industry

The "European Clinical Laboratory Services Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "European Clinical Laboratory Services Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.
  • According to a World Health Organization (WHO) study, although the segment accounts for less than 5% of hospital costs, its findings influence 60-70% of healthcare decision-making.
  • Diagnostics helps to analyze medical conditions and guide patients toward the right medication, treatment, or surgery.
  • Working largely unseen, laboratories are a vital link in the chain of activities required to keep populations safe from diseases.

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Retrieved on: 
Friday, December 17, 2021
People, DJSI, Hoffmann-La Roche, Omicron, RNA, Genentech, Severe acute respiratory syndrome coronavirus 2, Death, Central nervous system, PCR, Essential medicines, COVID-19 testing, Veni, vidi, vici, Cough, European Centre for Disease Prevention and Control, Public health, Organic acid, World, COVID-19, Severe acute respiratory syndrome coronavirus, Family, Saliva, Risk, JAMA Network Open, Dow Jones, RO, Patient, System, Coinfection, Infection, Collection, Coronavirus, COV, Virus, Control, Genetically modified bacteria, Joint Medical Service (Germany), Ophthalmology, Severe acute respiratory syndrome, CHF, Human, ROG, Pharmaceutical industry, Vaccine, Medical device, Fine chemical, Chugai Pharmaceutical Co.

PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.

Key Points: 
  • PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
  • Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
  • "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
  • The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.